Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02127710 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | PHASE2 | COMPLETED | 111 | — | — | Apr 30, 2014 | Apr 20, 2020 | Apr 19, 2021 | 23 | United States, Canada +2 |
The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.1.
The primary outcome measure was ORR, defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.
The primary outcome measure was ORR, defined as the proportion of patients with either a confirmed complete response/partial response by investigator assessment according to RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| AZD6094 600 mg daily continuously | EXPERIMENTAL | All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously. |
| Name | Type | Description |
|---|---|---|
| AZD6094 | DRUG | AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor. |
Inclusion criteria 1. Provision of informed consent prior to any study specific procedures, sampling and analyses. 2. Histologically confirmed PRCC, which is locally advanced or metastatic. 3. Availability of an archival tumor sample or a pre-treatment fresh tumor sample for confirmation of PRCC by...